Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Gerdes
Christian Gerdes, Erlenbach/zh CH
| Patent application number | Description | Published |
|---|---|---|
| 20100081796 | BISPECIFIC ANTI-EGFR/ANTI-IGF-1R ANTIBODIES - The present invention relates to bispecific antibodies against EGFR and against IGF-1R, methods for their production, pharmaceutical compositions containing said antibodies, and methods of treatment using the antibodies. | 04-01-2010 |
Christian Gerdes, Erlenbach CH
| Patent application number | Description | Published |
|---|---|---|
| 20110200595 | TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR - The present invention provides a humanized IgG-class anti-EGFR antibody and an anti-IGF-1R antibody for combined use in treating cancer, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also encompasses a pharmaceutical composition that is comprised of a combination of a humanized IgG-class anti-EGFR antibody and an anti-IGF-1R antibody in a pharmaceutically acceptable carrier. | 08-18-2011 |
Claus Gerdes, Rutihof CH
| Patent application number | Description | Published |
|---|---|---|
| 20120000577 | PROCESS FOR PRODUCING A SINGLE-CRYSTAL COMPONENT MADE OF A NICKEL-BASED SUPERALLOY - In a process for producing a large single-crystal component or directionally solidified component made of a nickel-based superalloy, the component is first cast into shape in a known manner to form a microstructure comprising dendrites, and then solution annealing for homogenizing the cast microstructure of the component and two-stage precipitation heat treatment are carried out. In order to avoid chemical inhomogeneities and internal stresses caused thereby, a HIP process with a pressure of higher than 160 MPa is carried out following the solution annealing. | 01-05-2012 |
Claus Paul Gerdes, Baden-Ruetihof CH
| Patent application number | Description | Published |
|---|---|---|
| 20110194972 | NICKEL-BASE SUPERALLOY WITH IMPROVED DEGRADATION BEHAVIOR - A nickel-base superalloy with improved degradation behavior consists essentially of the following chemical composition (details in % by weight): 7.7-8.3 Cr, 5.0-5.25 Co, 2.0-2.1 Mo, 7.8-8.3 W, 5.8-6.1 Ta, 4.9-5.1 Al, 1.3-1.4 Ti, 0.1-0.6 Pt, 0.1-0.5 Nb, 0.11-0.15 Si, 0.11-0.15 Hf, 200-750 ppm C, 50-400 ppm B, and the remainder Ni and production-related impurities. | 08-11-2011 |
Claus Paul Gerdes, Ruetihof CH
| Patent application number | Description | Published |
|---|---|---|
| 20120128527 | NICKEL-BASED SUPERALLOY - A nickel-base superalloy is characterized by the following chemical composition (details in % by weight): 7.7-8.3 Cr, 5.0-5.25 Co, 2.0-2.1 Mo, 7.8-8.3 W, 5.8-6.1 Ta, 4.9-5.1 Al, 1.0-1.5 Ti, 1.0-2.0 Re, 0.11-0.15 Si, 0.1-0.7 Hf, 0-0.5 Nb, 0.02-0.17 C, 50-400 ppm B, remainder Ni and production-related impurities. The alloy is distinguished by a very high resistance to oxidation, resistance to corrosion and good creep properties at high temperatures. | 05-24-2012 |
Claus Paul Gerdes, Rutihof CH
| Patent application number | Description | Published |
|---|---|---|
| 20100150727 | ROTOR BLADE FOR A GAS TURBINE - A rotor blade ( | 06-17-2010 |
Hans-Hermann Gerdes, Bergen NO
| Patent application number | Description | Published |
|---|---|---|
| 20090081775 | Microscope system and screening method for drugs, physical therapies and biohazards - Method and device for automated cell analysis and determination of transport and communication between living cells by analyzing the formation of tunneling nanotubes (TNTs) between cells. This method comprising the steps of singularizing cells in a culture medium and staining the cells with a fluorescent or luminescent dyes for staining of cytoplasm and membranes as well as TNTs, flagella and other cell particles for 3-D cell microscopy. The method comprises further an image analysis system. | 03-26-2009 |
Kenn Gerdes, Odense S DK
| Patent application number | Description | Published |
|---|---|---|
| 20080206840 | CYTOTOXIN-BASED BIOLOGICAL CONTAINMENT - Method of conditionally controlling the survivability of a recombinant cell population and of containing such cells to an environment or containing replicons to a host cell is based on the use of proteic killer systems including | 08-28-2008 |
Klaus Gerdes, Vienna AT
| Patent application number | Description | Published |
|---|---|---|
| 20090253743 | COMPOSITIONS OF TOLPERISONE - The present disclosure is directed to methods for providing tolperisone having extremely low levels of 4-MMPPO (2-methyl-1-(4-methylphenyl)-propenone), as well as related compositions. The invention further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO, among other features. | 10-08-2009 |
| 20100324090 | COMPOSITIONS OF TOLPERISONE - The present disclosure is directed to methods for providing tolperisone having extremely low levels of 4-MMPPO (2-methyl-1-(4-methylphenyl)-propenone), as well as related compositions. The invention further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO, among other features. | 12-23-2010 |
Klaus Gerdes, Wien AT
| Patent application number | Description | Published |
|---|---|---|
| 20100150995 | PROCESS FOR THE PRODUCTION OF HIGH-PURITY 2,4'-DIMETHYL-3-PIPERIDINO-PROPIOPHENONE (TOLPERISONE), PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THE LATTER, AS WELL AS ACTIVE INGREDIENT FORMULATIONS THAT CONTAIN TOLPERISONE - The invention relates to a method for producing highly pure 2,4′-dimethyl-3-piperidino-propiophenone (tolperisone) (formula I) and the pharmaceutically acceptable salts, hydrochlorides, and hydrates thereof. The method allows the content of the undesired byproduct 2-methyl-1-(4-methylphenyl) propenone (4-MMPPO) to be kept significantly lower than in previously known methods. The invention further relates to active substance formulations which contain tolperisone and are suitable, among other things, for producing combination preparations used for treating patients suffering from Alzheimer's disease. The invention also relates to topical formulations, controlled release (CR) formulations, and transdermal therapeutic systems, such as active substance patches, which contain less than 50 ppm, preferably less than 10 ppm, more preferably less than 7 ppm, and most preferably less than 3 ppm or 0 ppm (i.e. less than the detectable amount) of the undesired byproduct 2-methyl-1-(4-methylphenyl) propenone (4-MMPPO) in relation to 100 percent by weight of active substance. | 06-17-2010 |
Paul Claus Gerdes, Baden-Rutihof CH
| Patent application number | Description | Published |
|---|---|---|
| 20100206937 | WELDING ADDITIVE MATERIAL - A steel has the following chemical composition (amounts in % by weight): | 08-19-2010 |